Rate My Professor Gopala Rangan

Professor Rangan's research specializations encompass autosomal dominant polycystic kidney disease (ADPKD), clinical trials in kidney disease, gene therapy, and bioengineering. Over the last decade, he has spearheaded pivotal clinical trials and preclinical studies, notably the PREVENT-ADPKD randomized controlled trial published in the New England Journal of Medicine Evidence in 2021, which evaluated the efficacy and safety of prescribed water intake to suppress arginine vasopressin and slow cyst growth in ADPKD patients. Additional key publications include contributions to 'Evidence-Based Nephrology' on ADPKD (2022), KHA-CARI guidelines for the diagnosis and management of ADPKD (2016), and articles such as 'Standardised Outcomes in Nephrology—Polycystic Kidney Disease' (2017) and 'Recent advances in autosomal-dominant polycystic kidney disease' (2016). He chairs the Scientific Advisory Board of PKD Australia and participates in international initiatives like the Standardised Outcomes in Nephrology (SONG) for PKD. Professor Rangan's efforts aim to develop curative therapies for polycystic kidney disease within the next decade and he supervises PhD and Honours students in ADPKD, gene therapy, and bioengineering. His work has significantly influenced clinical management and research directions in genetic kidney diseases.